Philadelphia, PA (July 22, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates GBM Awareness Day this July and expresses its support for all those affected by this devastating form of brain cancer. Glioblastoma (GBM) is the most common type of malignant brain tumor among adults and is typically fatal. The two-year survival rate for GBM is less than 20%, and little progress has been made in battling brain cancer over the past 50 years.
ONC201, the company’s lead development candidate, is currently being tested in clinical trials for brain cancer, including GBM. Early results for the ONC201 trials are encouraging for a subtype of brain cancer called H3 K27M-mutant glioma. This mutation can occur in GBM and other gliomas, and clinical trial results with ONC201 in H3 K27M-mutant GBM patients are also encouraging. Details about the company’s trials can be found on clinicaltrials.gov: NCT03416530, NCT03295396, NCT03295396.
“In commemorating this day, we recognize not only the patients currently battling GBM but also the families of those patients, the clinicians and caregivers treating them, the survivors, the patients who have lost their lives, and the researchers working to defeat this disease,” said Lee Schalop, MD, Chief Executive Officer of Oncoceutics. “Over the last decades, little progress to secure new and effective treatments has been made in the battle against GBM, and there remains a strong need for new and innovative approaches to help change the future of this terrible disease.”
“Oncoceutics remains committed to changing the treatment landscape and drug development approach for brain cancer, and we are honored to work with leading cancer centers, researchers, and patient advocacy groups on that mission,” added Joshua Allen, PhD, Chief Scientific Officer of Oncoceutics. “We strongly support GBM Awareness Day in bringing national attention to this terrible disease, and encourage the public to support patient advocacy groups, learn more about the latest treatment options, and join us in commemorating this day.”
To learn more about GBM Awareness Day and how to get involved, visit:
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds called imipridones that selectively target G protein-coupled receptors for oncology. The first lead compound to emerge from this program is ONC201, an orally active small molecule DRD2 antagonist and ClpP agonist. The company is supported by grants from NCI, FDA, The Musella Foundation, and the National Brain Tumor Society, and a series of private and public partnerships. Visit Oncoceutics.com or contact Press@oncoceutics.com for more information.